STRC Research

hypb-regulatory-nof1-platform

4 min read

GROUNDING — N-of-1 bespoke therapy precedent and FDA platform technology designation

Source A — Baby KJ / CPS1 patient-specific base editing (NEJM)

  • Source: Musunuru K, Grandinette SA, Wang X, … Urnov FD, Ahrens-Nicklas RC. “Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease.” N Engl J Med 2025 Jun 12;392(22):2235-2243. doi:10.1056/NEJMoa2504747. Epub 2025 May 15. PMID 40373211. PMCID PMC12713542.
  • Accessed: 2026-08-21
  • Exact queries:
    1. WebSearch FDA platform technology designation N-of-1 personalized gene therapy baby KJ Muldoon CPS1 base editing individualized
    2. curl -s "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=Musunuru+personalized+base+editing+CPS1+infant&retmax=5&retmode=text" → PMID 40373211
    3. curl -s "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=40373211&rettype=abstract&retmode=text"

Verbatim abstract

“Base editors can correct disease-causing genetic variants. After a neonate had received a diagnosis of severe carbamoyl-phosphate synthetase 1 deficiency, a disease with an estimated 50% mortality in early infancy, we immediately began to develop a customized lipid nanoparticle-delivered base-editing therapy. After regulatory approval had been obtained for the therapy, the patient received two infusions at approximately 7 and 8 months of age. In the 7 weeks after the initial infusion, the patient was able to receive an increased amount of dietary protein and a reduced dose of a nitrogen-scavenger medication to half the starting dose, without unacceptable adverse events and despite viral illnesses. No serious adverse events occurred. Longer follow-up is warranted to assess safety and efficacy.”

Author affiliations include Children’s Hospital of Philadelphia, Penn, Innovative Genomics Institute (Berkeley), Broad Institute, Aldevron, Integrated DNA Technologies, Acuitas Therapeutics (LNP), and the Jackson Laboratory.

Evidential weight

  • STATES: a single named patient received a customized, lipid-nanoparticle-delivered genetic medicine designed for his own mutation; regulatory approval was obtained before dosing; the therapy was developed starting from diagnosis in a neonate and dosed at ~7 and ~8 months of age; the clinical readouts were surrogate/metabolic (increased dietary protein tolerance, halved nitrogen-scavenger dose), not a cure claim; “Longer follow-up is warranted”.
  • DOES NOT STATE: the regulatory route by name (IND / expanded access / platform designation), the cost, or the “six months” development timeline. Those appear only in secondary press (see below) and are flagged as SECONDARY.
  • SECONDARY (WebSearch synthesis over Innovative Genomics / NPR / BioSpace hits, same query as above, accessed 2026-08-21): “The process took about six months and cost less than $1 million.” Treat as press-reported, not peer-reviewed.
  • Target-organ note (relevant, and it cuts against transfer): CPS1 is a hepatic enzyme and the therapy was given by infusion. LNPs go to liver by default. This precedent is delivery-favourable in exactly the way STRC is not.

Source B — FDA Platform Technology Designation Program

Verbatim / near-verbatim passages (from search-result synthesis; SECONDARY weight)

“Platform Technology is defined in section 506K(h)(1) of the FD&C Act as a well-understood and reproducible technology, which can include a nucleic acid sequence, molecular structure, mechanism of action, delivery method, vector, or a combination of any such technologies that the sponsor demonstrates is incorporated in or used by a drug and is essential to the structure or function of such drug, and can be adapted for, incorporated into, or used by, more than one drug.”

“The U.S. FDA has granted Platform Technology Designation to Sarepta Therapeutics’ rAAVrh74 viral vector, the delivery component used in SRP-9003, an investigational gene therapy for limb-girdle muscular dystrophy type 2E/R4 (LGMD2E).”

“The designation is part of a new regulatory framework created under Section 506K of the Food, Drug, and Cosmetic Act and clarified in FDA’s May 2024 draft guidance.”

Evidential weight

  • STATES: section 506K exists; the statutory definition requires the technology be already incorporated in an approved drug-adjacent, well-understood and reproducible, and adaptable to more than one drug; the designation’s benefit is reuse of prior data across products sharing the component; at least one designation (Sarepta rAAVrh74, an AAV capsid, not an LNP) has been granted.
  • DOES NOT STATE: that any Moderna LNP or intismeran component has received platform technology designation. I found no source claiming intismeran holds a platform technology designation. Recorded explicitly so no claim leans on it.
  • DOES NOT STATE: any N-of-1-specific regulatory pathway by name. The KJ case establishes that FDA cleared a one-patient product; the mechanism by which it did (single-patient IND) is not grounded in any source I retrieved and must be labelled inference if used.

Graph View